Literature DB >> 11502861

A novel proliferation-associated variant of CFR-1 defined by a human monoclonal antibody.

F Hensel1, S Brändlein, M Eck, K Schmidt, V Krenn, A Kloetzer, A Bachi, M Mann, H K Müller-Hermelink, H P Vollmers.   

Abstract

The germline coded human monoclonal IgM antibody 103/51 was isolated from a gastric carcinoma patient. This antibody binds to a 130-kd membrane molecule and has a mitotic effect on tumor cells in vitro. To characterize the target, we sequenced the protein and showed that the antibody binds to the cysteine-rich fibroblast growth factor receptor (CFR)-1, which is highly homologous to MG-160 and the E-selectin-ligand (ESL)-1. The epitope was determined by glycosidase-digestion experiments to be an N-linked carbohydrate side chain. Immunohistochemistry was used to investigate the tissue distribution of CFR-1. Different healthy tissues were tested and only the collecting tubes of the kidney, the Golgi apparatus, and the glomerular and fascicular zones of the adrenal gland stained positive. However, on malignant tissue the receptor is overexpressed in nearly all tested stomach cancers (12 of 15) and other tested carcinomas (13 of 15). Most interestingly, the receptor is also present in Helicobacter pylori gastritis and gastric dysplasia, but absent on uninflamed stomach mucosa. This restricted tissue pattern indicates that antibody 103/51 reacts with a membrane-bound variant of CFR-1, which is mainly expressed on transformed cells and precursor lesions and is essential for proliferation processes. The possible activity of antibody 103/51 as an activating ligand in these proliferative changes of gastric epithelial mucosa is discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502861     DOI: 10.1038/labinvest.3780322

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  5 in total

1.  E-selectin ligand-1 regulates growth plate homeostasis in mice by inhibiting the intracellular processing and secretion of mature TGF-beta.

Authors:  Tao Yang; Roberto Mendoza-Londono; Huifang Lu; Jianning Tao; Kaiyi Li; Bettina Keller; Ming Ming Jiang; Rina Shah; Yuqing Chen; Terry K Bertin; Feyza Engin; Branka Dabovic; Daniel B Rifkin; John Hicks; Milan Jamrich; Arthur L Beaudet; Brendan Lee
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

Review 2.  Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention.

Authors:  Camille Jacqueline; Olivera J Finn
Journal:  Semin Immunol       Date:  2020-04-06       Impact factor: 11.130

Review 3.  Natural and adaptive IgM antibodies in the recognition of tumor-associated antigens of breast cancer (Review).

Authors:  Mariana Díaz-Zaragoza; Ricardo Hernández-Ávila; Rubí Viedma-Rodríguez; Diego Arenas-Aranda; Pedro Ostoa-Saloma
Journal:  Oncol Rep       Date:  2015-06-30       Impact factor: 3.906

Review 4.  Tumors: too sweet to remember?

Authors:  H Peter Vollmers; Stephanie Brändlein
Journal:  Mol Cancer       Date:  2007-12-04       Impact factor: 27.401

5.  2D immunoblots show differential response of mouse IgG and IgM antibodies to antigens of mammary carcinoma 4 T1 cells.

Authors:  Mariana Díaz-Zaragoza; Ricardo Hernández; Pedro Ostoa-Saloma
Journal:  Cancer Cell Int       Date:  2014-01-28       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.